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Abstract
Objective: An examination of whether oxycodone/naloxone prolonged-release tablets (OXN PR) can improve con-
stipation and maintain analgesia, compared with oxycodone prolonged-release tablets (OxyPR) in patients with moder-
ate/severe cancer pain.
Methods: Randomized, double-blind, active-controlled, double-dummy, parallel-group study in which 185 patients were
randomized to receive up to 120mg/day of OXN PR or OxyPR over 4 weeks. Efficacy assessments included Bowel
Function Index (BFI), Brief Pain Inventory Short-Form (BPI-SF), laxative and rescue medication use. Quality of life (QoL)
and safety assessments were conducted.
Results: After 4 weeks, mean BFI score was significantly lower with OXN PR; mean total laxative intake was 20% lower
with OXN PR. Mean BPI-SF scores were similar for both treatments and the average rate of analgesic rescue medication
use was low and comparable. QoL assessments were stable and comparable with greater improvements in constipation-
specific QoL assessments with OXN PR. Overall, rates of adverse drug reactions were similar.
Conclusions: OXN PR provides superior bowel function in cancer pain patients, compared with OxyPR, without
compromising analgesic efficacy or safety. This study confirms that OXN PR is well tolerated and efficacious in cancer
pain patients and results are in line with those seen in non-malignant pain patients.
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Introduction
Patients with cancer experience a wide variety of prob-
lems related not only to the disease itself, but often to
the treatments involved and their related side eﬀects.
Pain is a particular concern for cancer patients,
having a signiﬁcant impact on quality of life.1,2 More
than 80% of cancer patients with advanced metastatic
disease experience pain caused largely by direct tumour
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inﬁltration.2 Opioids are recommended for the manage-
ment of moderate/severe cancer pain by the WHO and
current guidelines,1–4 and are recognized as the treat-
ment of choice.2 The semi-synthetic opioid analgesic
oxycodone has become a cornerstone of pain manage-
ment in a wide range of settings,5 including cancer-
related pain.6,7 However, successful management of
pain with opioids requires that the beneﬁts of these
agents outweigh the impact of treatment-related side
eﬀects such as constipation.8,9 Up to 95% of patients
with cancer experience constipation, with highest inci-
dence observed in those who receive opioid therapy.10
This complication can cause further deterioration in the
quality of life of patients with cancer.
The eﬀects of opioids are determined by the location
of opioid receptors. Activation of opioid receptors in
the central nervous system results in analgesia, but acti-
vation of opioid receptors in the gut wall leads to
reduced gut motility, delayed gastric emptying,
increased sphincter tone and slower gut transit time.11
Consequently, patients can experience constipation,
gastro-oesophageal reﬂux, abdominal cramping,
spasm and bloating; collectively these symptoms are
known as opioid-induced bowel dysfunction.12,13
Opioid-induced constipation (OIC) is the most fre-
quently reported and persistent adverse event (AE) in
patients receiving opioid analgesia.14
Current management strategies for OIC are non-
speciﬁc, often ineﬀective and are largely lacking a
good evidence base.15 Laxatives are frequently used
and can be eﬀective, although many patients still do
not achieve adequate symptom relief, as they fail to
address the underlying opioid-related mechanisms.16,17
Use of peripherally acting opioid antagonists has been
identiﬁed as a promising approach; these agents speci-
ﬁcally target gastrointestinal (GI) receptors without
limiting the central analgesic activity of opioids.18,19
Naloxone is a peripherally acting opioid antagonist
with low systemic bioavailability (<3%) following
oral administration, due to extensive ﬁrst-pass hepatic
metabolism.20–22 Consequently, orally administered
naloxone acts almost exclusively on opioid receptors
in the GI tract.20,23 Targeting peripheral receptors
whilst sparing central analgesic function through com-
bining naloxone with oxycodone has emerged as a
promising approach for managing OIC, and generated
much academic and clinical interest.16,17,24
Three large, randomized, placebo-controlled Phase
III trials in patients with non-cancer pain,25–27 plus a
prospectively planned pooled analysis of two of these
studies,28 have already conﬁrmed analgesic eﬃcacy of
the combination of prolonged-release (PR) oxycodone/
naloxone (OXN PR), while also demonstrating beneﬁts
in terms of bowel function versus oxycodone PR
(OxyPR) alone. Importantly, OXN PR did not lead
to a reduction in analgesic eﬃcacy, compared with
OxyPR. Moreover, high analgesic eﬃcacy and a posi-
tive eﬀect on bowel function associated with OXN PR
have been shown in a long-term study,29 and in a large
observational study.30 The trials described above have
demonstrated the beneﬁts of the combination of oxy-
codone with naloxone in patients with chronic non-
cancer pain. Because opioid drugs are recommended
for the management of moderate/severe pain in
cancer patients,1–4,31 the aim of the current study was
to investigate whether OXN PR can also improve con-
stipation and maintain analgesia, compared with
OxyPR, in the cancer pain patient population.
Methods
Study design
The OXN2001 trial (ClinicalTrials.gov identiﬁer
NCT00513656)32 was a 4-week, international, multicen-
tre, randomized, double-blind, active-controlled,
double-dummy, parallel-group, Phase II study,
designed to evaluate the safety and eﬃcacy of OXN
PR in patients with moderate/severe chronic cancer
pain. The study was initiated on 2 November 2007
and the extension phase was completed on 17 August
2010. Following the screening period (3–10 days before
randomization), eligible patients stopped their pre-
study opioid and laxative medication and were ran-
domized (on Day 1/Visit 2) to switch directly to either
OXN PR or OxyPR during the 4-week double-blind
treatment phase. During the core phase of the study,
all subjects, investigators and sponsor personnel were
blinded. Treatments were masked in a double-dummy
fashion, whereby subjects randomized to receive OXN
PR were given OXN PR and OxyPR placebo, and sub-
jects randomized to receive OxyPR were given OxyPR
and OXN PR placebo. Patients attended three further
clinic visits (on Days 8, 15 and 29), and received four
additional telephone calls (on Days 2, 4, 6 and 22).
Patients could enter an open-label extension phase,
the details and results of which will be reported sepa-
rately. The study was performed in full compliance with
applicable Good Clinical Practice33 and regulations,
and in accordance with the Declaration of Helsinki.34
There were two primary objectives: (i) to determine
whether patients with moderate/severe cancer pain
taking OXN PR experience an improvement in symp-
toms of constipation, as measured by the validated
Bowel Function Index (BFI),35–37 compared with
patients taking OxyPR alone; and (ii) to compare eﬃ-
cacy for management of chronic cancer pain, as
assessed by the Brief Pain Inventory–Short Form
(BPI-SF).38 The secondary objectives included a
comparison of eﬀects on laxative and rescue medication
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use, quality of life (QoL) and safety. Regardless
of treatment group, patients were titrated up to a
maximum of 120mg/day oxycodone PR (if required).
Open-label oxycodone immediate-release capsules
(OxyIR) were available to patients as rescue medica-
tion, up to a maximum of six doses per 24 h. Patients
who needed to titrate up to oxycodone PR 120mg/day
and who regularly required two or more rescue doses
of OxyIR were withdrawn from the study. Bisacodyl
tablets were available as laxative rescue medication,
up to a maximum of ﬁve doses within seven consecutive
days.
Study population
Eligible patients were aged 18 years, with a diagnosis
of cancer and a documented history of moderate/
severe, chronic cancer pain, requiring round-the-clock
opioid therapy (equivalent to OxyPR 20–80mg/day at
the start of the trial). Subjects had to be willing and able
(e.g. mental and physical condition) to participate in all
aspects of the study, including use of medication, com-
pletion of subjective evaluations, attending scheduled
clinic visits, completing telephone contacts, and compli-
ance with protocol requirements as evidenced by pro-
viding written, informed consent. Patients were
excluded from the study for the following reasons: evi-
dence of clinically unstable disease or signiﬁcant cardio-
vascular, renal, hepatic or psychiatric disease; clinically
signiﬁcant GI disease, or signiﬁcant structural abnor-
malities of the GI tract; cyclic chemotherapy within 2
weeks before screening visit or planned during the core
study (shown in the past to inﬂuence bowel function);
radiotherapy that would inﬂuence bowel function or
pain during the double-blind phase.
Study assessments
Evaluations of bowel function (BFI),35–37 pain control
(BPI-SF),39 use of rescue medication and use of laxative
medication during the last 7 days were performed at each
clinic visit. The co-primary eﬃcacy variable was average
pain over the last 24 h based on BPI-SF (non-inferiority
bound 1.0). Co-primary eﬃcacy assessments were based
on changes from baseline after 4 weeks of treatment.
Quality-of-life assessments, including the European
QoL (EuroQoL) EQ-5D instrument40 and European
Organization for Research and Treatment of Cancer
QoL Questionnaire-Core 30 (EORTC QLQ-C30)41,42
were conducted at screening and study end. In addition,
Patient Assessment of Constipation Symptoms (PAC-
SYM) was conducted at screening, randomization and
4 weeks.43 Adverse events were noted at every assess-
ment post-randomization. In addition, vital signs, clin-
ical laboratory tests, physical examinations and 12-lead
electrocardiographs (ECGs) were conducted through-
out the study. Patients were followed up regarding
AEs and adverse drug reactions (ADRs) after study
completion. At randomization, Days 2, 4, 6 and 8,
patients were asked about symptoms of opiate with-
drawal (using the modiﬁed Subjective Opiate
Withdrawal Scale [SOWS]).27,44
Randomization and sample size calculation
Patients were assigned to treatments (1:1 allocation
ratio) using a pseudo-random number generator in a
computer program. During visit 2, eligible subjects
were randomized to one of two treatment groups (i.e.
OXN PR or OxyPR) according to a randomization
schedule prepared by the Clinical Supplies
Department of the Sponsor or an associated company.
Treatment assignments were randomized within blocks
of ﬁxed size. No stratiﬁcation was done. The study was
designed to have a power of 80% to detect a treatment
diﬀerence of 12 on the BFI on a two-sided level of sig-
niﬁcance of a¼ 0.05 assuming a common standard
deviation (SD) of 26.
Non-inferiority of OXN PR to OxyPR regarding
pain intensity could be concluded on a one-sided level
of signiﬁcance of a¼ 0.05 assuming a non-inferiority
bound of 1.0 and a common SD of 2.0.
Statistical analysis
For the primary analyses, analysis of covariance
(ANCOVA) was used to compare treatments regarding
primary and co-primary endpoints at 4 weeks, adjusting
for baseline observation, and using the last observation
carried forward (LOCF) approach for missing values.
For the BFI, the null hypothesis was a zero diﬀerence
(on average) between treatment groups at the ﬁnal visit.
The alternative hypothesis was that there is a diﬀerence
between the treatment groups. Two-sided tests were per-
formed at the 5% signiﬁcance level. For BPI-SF, the
null hypothesis was a diﬀerence of 1 (on average)
between treatment groups at the ﬁnal visit, in favour
of Oxy PR (OXN PR inferior to OxyPR). The alterna-
tive hypothesis was a diﬀerence greater than 1 (OXN
PR non-inferior to Oxy PR). One-sided t-tests were per-
formed at the 5% signiﬁcance level.
Additional sensitivity analyses were performed for
co-primary endpoints using the same ANCOVA anal-
yses on the non-LOCF data and baseline observation
carried forward (BOCF) data. Mixed-eﬀects models for
repeated measures (MMRM) analyses were also con-
ducted, adjusting for visit and treatment3 visit interac-
tion, and assuming a constant treatment eﬀect over
visits in respective MMRM analyses. For other eﬃcacy
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outcomes and safety data, summary statistics were
produced.
Results
Patient disposition
Of 224 enrolled patients, 185 were randomized, 184 were
part of the double-blind safety population and 183 were
included in the full analysis population I; the full analysis
population II consisted of 157 patients and the per-pro-
tocol population of 133 patients. During the blinded
data evaluation it was recognized that 28 patients ran-
domized dropped out early but not due to AE constipa-
tion and not due to lack of eﬀect. It was decided at a
blinded stage to exclude those subjects from the full
analysis population I as those patients would not give
valid information about the drug eﬀects regarding BFI if
the distribution was not equal in both treatments arms.
The primary analysis (superiority testing) of BFI was
performed in an intention-to-treat manner on the full
analysis II population. The patient dispositions and
study populations are shown in Figure 1A and B.
Overall, 133/184 (72.3%) patients completed the study.
Rates of discontinuation were similar for OXN PR (26/
92 [28.3%]) and OxyPR (25/92 [27.2%]). In both groups,
the primary reason for discontinuation was AEs (OXN
PR, n¼ 20; OxyPR, n¼ 12).
Patient demographics and baseline characteristics
Demographic characteristics were well balanced
between treatment groups. The only exception to
Figure 1. (a) Patient disposition; (b) study populations. The double-blind safety population included all patients who received any dose
of study medication; the full-analysis population I excluded one patient from the double-blind safety population who did not receive
treatment and was hence not included in the analysis; the full-analysis population II excluded those patients from the original full-analysis
population who discontinued due to AEs other than constipation or lack of efficacy within the first 14 days (in order to obtain reliable BFI
values and prevent possible skewing due to these early withdrawals); the per-protocol population included patients who received at least
one dose of study medication during the double-blind phase and who sufficiently complied with the study protocol. OXN PR: oxycodone/
naloxone prolonged-release tablets, OxyPR: oxycodone prolonged-release tablets, AE: adverse event, BFI: Bowel Function Index.
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this was a slightly higher percentage of patients
aged 65 years in the OXN PR group, compared
with the OxyPR group (65.2 vs. 48.9%, respectively;
Table 1). At the start of the study, 183/184 (99.5%)
patients suﬀered from constipation induced or wors-
ened by their opioid medication (OXN PR 92/92
[100%]; OxyPR 91/92 [98.9%], the one subject in
the OxyPR group had constipation in their medical
history but it was not recorded as ongoing at visit 1;
Table 1). A similar number of subjects in each
treatment group took laxatives (96.7% in the
OxyPR group and 95.7% in the OXN PR group).
The most frequently taken laxatives were lactulose,
bisacodyl and sennoside. At baseline, the most fre-
quently reported primary cancer sites were breast
(19%), lung (13%) and prostate (10%). Twenty-
six per cent of patients had bone metastases. Most
frequently used pre-study opioids were fentanyl
(29%), morphine (79%), oxycodone (85%) and trama-
dol (35%).
Exposure to study medication
The majority of patients in the OXN PR and OxyPR
groups received study medication for 4 weeks (59.8
vs. 67.4%, respectively), and had similar mean (SD)
durations of study participation (23.58 [9.54] vs. 25.05
[8.37] days, respectively) and daily doses (46.59 [22.58]
vs. 43.09 [19.31] mg/day, respectively).
Efficacy
Primary endpoints. Perception of constipation varies
from patient to patient and results from three random-
ized controlled trials have shown that the BFI is a val-
idated, easy-to-use questionnaire for the measurement
of opioid induced constipation.35 It is a three-item
questionnaire that takes into account subjective criteria
often reported by the patient. Using analysis of stan-
dard error of measurements and one-half SD charac-
teristics of each BFI component, Rentz et al. reported
that changes in BFI score 12 points represent clini-
cally meaningful changes while score changes of less
than 7.5 points are unlikely to be clinically meaningful
in patient’s perception of their bowel habits.35 At ran-
domization, mean (SD) BFI values were high and com-
parable in the OXN PR and OxyPR groups (63.97
[17.42] vs. 62.40 [23.56], respectively), and similar to
baseline assessments in previous OXN PR Phase III
trials,25–27 indicating that patients suﬀered from consti-
pation caused or aggravated by opioid medication. The
diﬀerence in change from baseline in BFI score (DBFI)
between groups was statistically signiﬁcant (LOCF,
Table 1. Patient demographics and clinical characteristics (double-blind safety population)
OXN PR OxyPR
Variable n¼ 92 n¼ 92
Age, years
Mean (SD) 61.86 (10.93) 64.30 (9.63)
Median (range) 62.0 (36–84) 66.0 (42–82)
Age group, n (%)
65 years 60 (65.2) 45 (48.9)
>65 years 32 (34.8) 47 (51.1)
Sex, n (%)
Male 48 (52.2) 46 (50.0)
Female 44 (47.8) 46 (50.0)
Race, n (%)
Caucasian 92 (100.0) 91 (98.9)
Black 0 (0) 1 (1.1)
Constipation induced or worsened by opioid medication, n (%) 92 (100.0) 91 (98.9)
n¼ 90 n¼ 90
Body mass index, kg/m2
Mean (SD) 25.34 (5.75) 25.62 (5.13)
Median (range) 24.7 (15–39) 25.6 (16–41)
SD: standard deviation, OXN PR: oxycodone/naloxone prolonged-release tablets, OxyPR: oxycodone prolonged-release tablets.
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DBFI¼11.14; 95% conﬁdence interval [CI]: 19.03
to 3.24; p< 0.01) These ﬁndings were underlined by
the results of MMRM (with treatment by visit interac-
tion, DBFI¼10.8; 95% CI: 18.8 to 2.8; p¼ 0.018),
MMRM (assuming a constant treatment eﬀect,
DBFI¼12.36; 95% CI: 19.05 to 5.67; p< 0.01),
BOCF (DBFI¼10.85; 95% CI: 18.63 to 3.073;
p< 0.01 and LOCF analyses (per-protocol population:
DBFI¼14.78; 95% CI: 23.03 to 6.53; p< 0.01). A
statistically signiﬁcant diﬀerence between treatments in
favour of OXN PR was observed already at week 1.
Taking all analyses into account, OXN PR is both sta-
tistically signiﬁcantly superior in respect to BFI and has
also demonstrated a change that is clinically relevant.
At randomization, mean (SD) BPI-SF scores were
comparable for OXN PR and OxyPR treatment
groups (4.16 [1.87] vs. 4.18 [1.87]). There was a slight
decrease in mean BPI-SF scores, which was similar
between groups. After 4 weeks of treatment, mean
(SD) BPI-SF scores remained comparable between
OXN PR and OxyPR groups (3.50 [1.88]) and 3.52
[1.80]; Figure 2B). Results of the primary analysis con-
ﬁrmed non-inferiority of OXN PR to OxyPR (LOCF,
least squares [LS] mean diﬀerence 0.011; 90% CI:
0.47 to 0.45, p< 0.01). Non-inferiority in pain was
further supported by sensitivity analyses, including
MMRM, LOCF and BOCF.
Secondary endpoints. After 4 weeks, mean (SD) total
laxative (oral bisacodyl) intake was 20% lower in the
OXN PR group than the OxyPR group (26.10 [27.60]
vs. 32.69 [31.26] mg, respectively), but the diﬀerence
was not statistically signiﬁcant (p¼ 0.17). The need
for rescue analgesic medication was generally low in
both treatment groups throughout the double-blind
phase, in terms of both frequency (less than one
intake/day) and dose. Diﬀerences between groups
were not signiﬁcant for either variable (p¼ 0.4 and
p¼ 0.22, respectively). Over 4 weeks of treatment,
PAC-SYM scores improved in both groups, but the
degree of improvement at endpoint was signiﬁcantly
greater for OXN PR than for OxyPR, in terms of
total symptom score (p¼ 0.014) and frequency of symp-
toms (p< 0.01; Table 2). These results are in line with
results of BFI analyses, conﬁrming better bowel eﬃcacy
of OXN PR, compared with OxyPR.
At screening, mean EQ-5D index scores were com-
parable between treatment groups. After 4 weeks,
mean (SD) index score was 0.50 (0.33) for OXN PR
and 0.49 (0.38) for OxyPR. All mean (SD) EORTC
QLQ-C30 scores were comparable between treatment
groups at randomization. Mean pain subscore
improved in both groups. Importantly, the mean
(SD) constipation subscore in the OXN PR group
was 44.32 (35.16) after 4 weeks of treatment (mean
change from screening, 30.4), compared with a sub-
score of 59.78 (35.13) in the OxyPR group (mean
change, 13.1). The improvement in this quality of
life measure correlates well with the improvement
seen measured by the BFI (R¼ 0.71)
Safety
The proportion of patients who experienced AEs
or ADRs was generally similar for OXN PR and
OxyPR groups (Table 3). Approximately 20% of AEs
were due to progression of underlying cancer disease.
The most frequently reported AEs were GI disorders
and ‘general disorders and administration site condi-
tions’. The proportions of each group with ADRs
were comparable for OXN PR and OxyPR (38.0 vs.
34.8%, respectively).
The incidence of serious ADRs was low in both
groups (Table 3). In total, 18 patients (9.8%) died
during the study, with nine in each group. No death
was considered related to study medication (progres-
sion of malignant disease n¼ 16; cardiac disorders
n¼ 2). There were no clinically important changes in
vital signs, laboratory values, ECG assessments or
modiﬁed SOWS observed. Mean (SD) SOWS values
at baseline were 8.01 (7.76) and 8.90 (7.81) for OXN
PR and OxyPR, respectively. These remained stable
throughout the assessment period (OXN PR 6.64
[5.97]; OxyPR 7.29 [4.59] at last assessment).
Discussion
Opioids are widely recommended to relieve pain in
cancer patients,3,4,31,45 but are associated with AEs
such as constipation. Results from this study demon-
strate that OXN PR provides comparable analgesia to
OxyPR for patients with moderate/severe cancer pain,
whilst signiﬁcantly improving bowel function and
reducing symptoms of constipation.
OXN PR was superior to OxyPR with respect to
bowel function, particularly reducing constipation, as
measured by the BFI. Importantly, the diﬀerence
between the two treatments was both statistically sig-
niﬁcant and clinically relevant and, moreover, achieved
with less laxative use with OXN PR (20% less). In fact,
there was already a statistically signiﬁcant beneﬁt in
BFI score for OXN PR, compared with OxyPR, after
1 week. Overall, achieving this improvement in BFI
with reduced laxative use in the OXN PR group, in
such a short time frame, is encouraging, considering
the severity of underlying disease and the nega-
tive impact of constipation on the lives of can-
cer patients.9,10 Primary eﬃcacy ﬁndings were
underlined by signiﬁcant diﬀerences in PAC-SYM
domain scores in favour of OXN PR.
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With respect to the co-primary endpoint of pain
relief, OXN PR was non-inferior to OxyPR, as mea-
sured by BPI-SF. Rescue analgesic use was low and
comparable between groups throughout the double-
blind phase, showing that patients were eﬀectively
titrated to a stable dose of study medication, and that
comparable analgesic eﬃcacy of OXN PR and OxyPR
was not inﬂuenced by diﬀerential use of rescue analge-
sic medication.
General QoL results using EQ-5D and EORTC
QLQ-C30 were similar for OXN PR and OxyPR treat-
ments over time. However, results of the speciﬁc
Figure 2. Effect of OXN PR and OxyPR treatment on (a) mean (6 standard error) BFI score (full analysis population II, LOCF); and
(b) mean (6 standard error) BPI-SF score (per-protocol population, LOCF), by study day. aPopulations varied at each day. Error bars
represent standard error; OXN bp-value and confidence interval for treatment difference adjusted for baseline using an ANCOVA
model. (a) BFI: 95% CI19.03 to 3.24; (b) BPI-SF: 90% CI0.47 to 0.45. OXN PR: oxycodone/naloxone prolonged-release tablets,
OxyPR: oxycodone prolonged-release tablets, BFI: bowel function index. (Copyright for the BFI is owned by Mundipharma Research,
2002; the BFI is the subject of European Patent Application Publication No. EP 1 860 988 and corresponding patents and applications in
other countries).
56 Palliative Medicine 26(1)
EORTC QLQ-C30 constipation subscore indicated
that OXN PR patients had a superior outcome, com-
pared with OxyPR patients. This could contribute
towards an improved quality of life for many patients
with chronic cancer pain treated with OXN PR.
There were slightly more dropouts due to AEs in
the OXN PR group, although the overall incidence of
AEs was comparable between treatment groups. Most
frequently reported ADRs were consistent with the
known safety proﬁle of the opioid analgesic class of
drugs, and with those seen in previous Phase III trials
of OXN PR in patients with non-cancer pain.26,27
There were slightly more total GI disorders observed
in the OXN PR group; however, the incidence of the
most frequent AEs such as abdominal pain, worsened
constipation, diarrhoea and vomiting were compara-
ble, whilst nausea was reported less commonly in the
OXN PR group. Therefore, the slightly higher number
of total GI disorders in the OXN PR group is
explained by the sum of less frequent AEs. It is pos-
sible that GI-related AEs indicate return of more
active bowel function (as is aimed for when treating
constipated patients), which has also been documented
after use of other peripherally acting opioid antago-
nists, such as methylnaltrexone.46 In a study compar-
ing methylnaltrexone with placebo, in patients
receiving the active drug, abdominal pain also
occurred more frequently. In addition, more ﬂatulence
and nausea were reported for methylnaltrexone;46 this
was not seen with OXN PR in the study described
here. There were no clinically relevant changes in lab-
oratory values or vital signs related to study medica-
tion. Mean modiﬁed SOWS values were low and
comparable in both groups. In summary, the results
suggest that switching from other opioids to oxyco-
done – as either OXN PR or OxyPR – was generally
safe and well tolerated by patients in this trial, with
switching to OXN PR giving the added beneﬁt of
reduced OIC complications.
The ﬁndings of this study should be interpreted
within the context of the trial design and patient pop-
ulation. The double-blind phase had a duration of 4
weeks to allow for assessment of analgesic eﬀect, con-
sistent with European Medicines Agency guidelines on
clinical studies of chronic moderate/severe cancer
pain.47 This timeframe is also deemed adequate for
observing diﬀerences in constipation based on previous
Phase II48 and Phase III data.27
Although the demographic proﬁle of both treatment
groups was generally similar there was a slightly higher
percentage of patients aged 65 years in the OXN PR
group than in the OxyPR treatment group. However,
this diﬀerence is not clinically relevant, as results from
previous clinical studies have demonstrated that the
eﬃcacy and safety of OXN PR in older patients is sim-
ilar to that in younger patients.49 Additional assess-
ments showed that there was no correlation between
BFI score at study end (LOCF) and age (data not
shown).
Opioid-induced bowel dysfunction is common and
adds to the burden of living with chronic pain. Current
oral and rectal laxatives are often ineﬀective and do not
have a good evidence base.15 The new targeted
approach of administering peripherally acting opioid
antagonists is eﬀective and is supported by extensive
clinical trial data. Previous attempts to use immedi-
ate-release naloxone were unsuccessful because of
reversal of analgesia; and the only other licensed
peripherally acting opioid antagonist, methylnaltrex-
one, has to be given by injection.15,46 The present
trial has shown that oral OXN PR tablets are well
tolerated and can eﬀectively and conveniently provide
targeted treatment of OIC at a dose range which
includes a substantial proportion of patients with
cancer pain.
Conclusion
In this study of patients with OIC and moderate/severe
cancer pain, patients who were switched directly from
other opioids to OXN PR experienced a similar anal-
gesic eﬀect as well as a statistically signiﬁcant and
Table 2. Patient assessment of constipation using PAC-SYM
(Full-Analysis II population)
Parameter OXN PR, n¼ 77 OxyPR, n¼ 80
Total symptoms score
Day 1
n 75 80
Mean (SD) 17.38 (6.99) 18.21 (8.28)
Median (range) 17.0 (2–32) 16.0 (0–42)
At 4 weeks
n 73 74
Mean (SD) 10.37 (8.57) 15.47 (9.83)
Median (range) 8.0 (0–37) 14.0 (0–37)
OXN PR versus OxyPR p< 0.01
Frequency of symptoms
Day 1
n 75 79
Mean (SD) 2.53 (1.09) 2.33 (1.07)
Median (range) 3.0 (0–4) 3.0 (0–4)
At 4 weeks
n 73 73
Mean (SD) 1.47 (1.07) 2.03 (1.29)
Median (range) 1.0 (0–4) 2.0 (0–4)
OXN PR versus OxyPR p< 0.01
PAC-SYM: Patient Assessment of Constipation Symptoms, SD: standard
deviation, OXN PR: oxycodone/naloxone prolonged-release tablets,
OxyPR: oxycodone prolonged-release tablets.
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clinically relevant improvement in bowel function,
compared with those switched to OxyPR. Overall,
these data are in line with results of previous Phase
III trials demonstrating analgesic eﬃcacy and tolerabil-
ity of OXN PR, suggesting that the combination of
oxycodone and naloxone is suitable across the spec-
trum of patients with cancer and non-cancer pain.
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